Recce Pharmaceuticals Enters Into Research Agreement With US Army Institute of Surgical Research

MT Newswires Live

Feb 02

Recce Pharmaceuticals (ASX:RCE) entered into a cooperative research and development agreement with the United States Army Institute of Surgical Research to evaluate its RECCE 327 gel therapy candidate in their validated Walker-Mason rat model of burn wound infection, according to a Monday Australian bourse filing.

The study will evaluate whether the gel can significantly reduce bacterial burden in infected burn wounds against methicillin-resistant bacterial pathogens, Staphylococcus aureus and Pseudomonas aeruginosa.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2608882648"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2608882648\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2608882648?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-02 07:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608882648","market":"sg","top_or_hot":-1,"title":"Recce Pharmaceuticals Enters Into Research Agreement With US Army Institute of Surgical Research","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/RECEF\">Recce Pharmaceuticals</a> (ASX:RCE) entered into a cooperative research and development agreement with the United States Army Institute of Surgical Research to evaluate its RECCE 327 gel therapy candidate in their validated Walker-Mason rat model of burn wound infection, according to a Monday Australian bourse filing.</p><p>The study will evaluate whether the gel can significantly reduce bacterial burden in infected burn wounds against methicillin-resistant bacterial pathogens, Staphylococcus aureus and Pseudomonas aeruginosa.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Recce Pharmaceuticals Enters Into Research Agreement With US Army Institute of Surgical Research</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRecce Pharmaceuticals Enters Into Research Agreement With US Army Institute of Surgical Research\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-02 07:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/RECEF\">Recce Pharmaceuticals</a> (ASX:RCE) entered into a cooperative research and development agreement with the United States Army Institute of Surgical Research to evaluate its RECCE 327 gel therapy candidate in their validated Walker-Mason rat model of burn wound infection, according to a Monday Australian bourse filing.</p><p>The study will evaluate whether the gel can significantly reduce bacterial burden in infected burn wounds against methicillin-resistant bacterial pathogens, Staphylococcus aureus and Pseudomonas aeruginosa.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RCE.AU","symbol_name":"RECCE PHARMACEUTICALS LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2608882648","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608882648","pubTimestamp":1769987208,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Recce Pharmaceuticals  entered into a cooperative research and development agreement with the United States Army Institute of Surgical Research to evaluate its RECCE 327 gel therapy candidate in their validated Walker-Mason rat model of burn wound infection, according to a Monday Australian bourse filing.The study will evaluate whether the gel can significantly reduce bacterial burden in infected burn wounds against methicillin-resistant bacterial pathogens, Staphylococcus aureus and Pseudomonas aeruginosa.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RCE.AU":"RECCE PHARMACEUTICALS LTD","BK7096":"制药"},"translate_title":"Recce Pharmaceuticals与美国陆军外科研究所签订研究协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RCE.AU":1},"content_text":"Recce Pharmaceuticals (ASX:RCE) entered into a cooperative research and development agreement with the United States Army Institute of Surgical Research to evaluate its RECCE 327 gel therapy candidate in their validated Walker-Mason rat model of burn wound infection, according to a Monday Australian bourse filing.The study will evaluate whether the gel can significantly reduce bacterial burden in infected burn wounds against methicillin-resistant bacterial pathogens, Staphylococcus aureus and Pseudomonas aeruginosa.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}